Went public 6/16/2000 at $10 apiece
Filing Range: 4.5 mil. shares @ $12 to $14
Shares Outstanding: 20.76 mil. shares
Underwriters: Prudential Vector Healthcare/Pacific Growth
Equities Inc./SG Cowen Securities Corp.
Company Counsel: Cooley Godward LLP
Manager Counsel: Skadden, Arps, Slate, Meagher & Flom
Auditor: Ernst & Young LLP
Develops cell therapies for the treatment of cancer and viral infections. Its products feature the use of antigen pulsed dendritic cells as therapeutic agents. The company also develops immunotherapy for prostate cancer in order to stimulate the immune response and delay the progression of the disease.
Healthcare Ventures LLC
Vulcan Ventures Inc.
New York Life Venture Capital Group
Shaw Venture Partners
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 01/01/1996 6 Early Stage 6232.0
2 08/12/1997 7 Early Stage 12000.0
3 07/31/1998 5 Expansion 4700.0
4 09/16/1999 5 Later Stage 13179.9
5 02/01/2000 1 Later Stage 4130.0 59
(Data in $ millions)
Total Revenues: $3.51
Net Loss: -12.96